MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sales and
maturities of short-term...
$101,766K
Proceeds from issuance of
common...
$10,364K
Proceeds from exercise of
stock options and...
$282K
Net cash provided by
(used in) investing...
$75,120K
Net cash provided by
financing activities
$10,451K
Effect of exchange rate
changes on cash, cash...
$1,036K
Canceled cashflow
$26,646K
Canceled cashflow
$195K
Net increase in
cash, cash...
$20,652K
Canceled cashflow
$65,955K
Purchase of short-term
investments
$26,511K
Purchases of property,
plant and equipment...
$135K
Stock-based compensation
expense
$7,047K
Depreciation and
amortization
$848K
Finance lease,
right-of-use-asset amortization
$607K
Noncash interest
expense
$425K
Operating lease,
right-of-use-asset amortization
$194K
Prepaid expenses and
other current assets
-$36K
Principal payment of
finance lease...
$195K
Net cash used in
operating activities
-$65,955K
Canceled cashflow
$9,157K
Net loss
-$70,930K
Accrued expenses and
other current...
-$1,913K
Accounts payable
-$730K
Unrealized foreign
currency transaction...
$581K
Research and development
incentives receivable
$349K
Other non-current
liabilities
-$268K
Operating lease
liabilities
-$207K
Net amortization of
premiums and discounts on...
$134K
Back
Back
Cash Flow
source: myfinsight.com
Replimune Group, Inc. (REPL)
Replimune Group, Inc. (REPL)